Outset Medical Inc
$ 4.57
-3.79%
31 Jul - close price
- Market Cap 84,715,000 USD
- Current Price $ 4.57
- High / Low $ 4.79 / 4.47
- Stock P/E N/A
- Book Value 6.03
- EPS -2.74
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.15 %
- ROE -0.53 %
- 52 Week High 17.20
- 52 Week Low 3.00
About
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. The company is headquartered in San Jose, California.
Analyst Target Price
$7.67
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-11 | 2025-11-10 | 2025-08-06 | 2025-05-07 | 2025-02-19 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-02-21 | 2023-11-07 | 2023-08-02 |
| Reported EPS | -0.83 | -0.84 | -0.69 | -0.84 | -3.24 | -5.55 | -5.85 | -7.05 | -8.55 | -8.85 | -10.65 | -10.35 |
| Estimated EPS | -0.79 | -0.67 | -0.65 | -0.98 | -0.94 | -6.19 | -6.32 | -6.79 | -8.23 | -9.22 | -10 | -10.89 |
| Surprise | -0.04 | -0.17 | -0.04 | 0.14 | -2.3 | 0.64 | 0.47 | -0.26 | -0.32 | 0.37 | -0.65 | 0.54 |
| Surprise Percentage | -5.0633% | -25.3731% | -6.1538% | 14.2857% | -244.6809% | 10.3393% | 7.4367% | -3.8292% | -3.8882% | 4.013% | -6.5% | 4.9587% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.88 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OM
2026-07-29 19:04:01
BlackRock, Inc. has filed an amended Schedule 13G, disclosing its beneficial ownership of 365,556 shares of Outset Medical, Inc. common stock, which represents 2.0% of the outstanding class. The filing indicates BlackRock holds sole voting and dispositive power over these shares, with no shared power. While various persons have rights to dividends or sale proceeds, no individual interest exceeds five percent of Outset Medical's total outstanding common shares.
2026-07-29 15:09:48
Halper Sadeh LLC is investigating whether certain officers and directors of Outset Medical, Inc. breached their fiduciary duties to shareholders. The law firm is offering to handle claims on a contingent fee basis, meaning shareholders will not incur upfront legal costs. This investigation aims to achieve corporate governance reforms, provide financial incentives, or offer other relief to long-term shareholders if misconduct is proven.
2026-07-27 13:20:22
This article provides a detailed cash flow statement for Outset Medical Inc (OM), presenting quarterly and annual figures for operating, investing, and financing activities. It includes year-over-year changes for various cash flow components and explains key financial terms like operating cash flow, investing cash flow, financing cash flow, and free cash flow. The data highlights the company's financial performance and changes in its cash management over several fiscal years.
2026-07-27 10:42:16
Outset Medical Inc. (OM) is a medical technology company specializing in the Tablo Hemodialysis System, a comprehensive solution for dialysis delivery. The system integrates water purification and on-demand dialysate production. The article outlines the company's background, financial data, key executives, and institutional shareholding information.
2026-07-25 07:11:46
This article provides a risk assessment for Outset Medical Inc (OM), detailing its current risk score, industry ranking, and volatility measures. It highlights the company's beta value of 1.94, indicating higher sensitivity to market movements compared to the S&P 500. Various metrics including maximum drawdown, daily returns, Sharpe ratio, and volatility are presented to give a comprehensive overview of investment risks.
2026-07-24 15:42:31
Outset Medical Inc. (OM) is currently trading at $4.04, down 4.49%. Despite recent market underperformance, the company shows stable fundamentals and significant growth potential, with analysts rating it a "Buy" and a target price of $7.67. The company specializes in the Tablo Hemodialysis System, an all-in-one solution for dialysis delivery.
